Continued Guideline-Directed Medical Therapy

Approved

Continued Guideline-Directed Medical Therapy is one of 4 therapeutic programs targeting Heart Failure With Reduced Ejection Fraction. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Heart Failure With Reduced Ejection FractionNot yet recruiting

Heart Failure With Reduced Ejection FractionApproved

Not yet recruiting

Competition

Competitive Landscape

8 competitors in Heart Failure With Reduced Ejection Fraction

#DrugCompanyPhaseTrials

Continued Guideline-Directed Medical Therapy

KKyungsub Song

Approved

1 2

Lumacaftor

Vertex Pharmaceuticals

Phase 2

1 3

Ozempic

Novo Nordisk

Preclinical

1 4

HJB647 Low Dose

Novartis

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

ApprovedNot yet recruiting

Heart Failure With Reduced Ejection Fraction

NCT07631156

Clinical

Trials by Indication[1]

Heart Failure With Reduced Ejection Fraction1 trial

STEPwise De-escalation and Optimizing Withdrawal of ARNI and SGLT2i in Normalized Heart Failure (STEP-DOWN HF Trial)

Not yet recruiting·KKyungsub Song·Approved·NCT07631156·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Continued Guideline-Directed Medical Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Continued Guideline-Directed Medical Therapy. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Kyungsub Song company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Approved[1]
Company: KKyungsub Song

Continued Guideline-Directed Medical Therapy

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Heart Failure With Reduced Ejection Fraction1 trial

References

Drug Info

Quick Facts

Related News